Former Pfizer R&D chief, Mikael Dolsten, withdraws candidacy for Novo Nordisk board due to personal reasons. He has held senior R&D roles at Boehringer Ingelheim and AstraZeneca. Other board candidates unchanged. Novo Nordisk faces changes as top investor aims for U.S. market focus and shareholder backlash looms over board shake-up.

Read more at Yahoo Finance: Pfizer’s ex-R&D chief Dolsten withdraws from Novo Nordisk board race